Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Operating Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Operating Expenses for 15 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 33.83% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, changed 0.04% year-over-year, with the annual reading at $20.5 million for FY2025, 0.04% changed from the prior year.
  • Operating Expenses for Q4 2025 was $7.1 million at Plus Therapeutics, up from $5.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $7.1 million in Q4 2025, with the low at $2.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $4.6 million, with a median of $5.0 million recorded in 2024.
  • The sharpest move saw Operating Expenses surged 150.64% in 2021, then plummeted 41.16% in 2025.
  • Over 5 years, Operating Expenses stood at $3.5 million in 2021, then surged by 63.56% to $5.7 million in 2022, then decreased by 9.65% to $5.2 million in 2023, then rose by 2.73% to $5.3 million in 2024, then skyrocketed by 33.83% to $7.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $7.1 million, $5.9 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.